First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of geriatric oncology"
DOI: 10.1016/j.jgo.2020.06.003
Abstract: BACKGROUND Despite the high morbidity and mortality of metastatic colorectal cancer (mCRC) in older patients, they have been underrepresented in clinical trials and their optimal treatment is yet to be determined. This open-label phase II… read more here.
Keywords: metastatic colorectal; plus capecitabine; months median; treatment ... See more keywords
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2980
Abstract: Purpose: Pembrolizumab demonstrated efficacy in PD-L1–positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (G/GEJ) cancer in the first-, second-, and third-line setting in KEYNOTE-062, KEYNOTE-061, and KEYNOTE-059, respectively. To better delineate the specificity of… read more here.
Keywords: months versus; combined positive; efficacy; versus months ... See more keywords
Sex differences in patient journeys to diagnosis, referral, and surgical treatment of trigeminal neuralgia: implications for equitable care.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of neurosurgery"
DOI: 10.3171/2022.11.jns221191
Abstract: OBJECTIVE Trigeminal neuralgia (TN) is an orofacial pain disorder that is more prevalent in females than males. Although an increasing number of studies point to sex differences in chronic pain, how sex impacts TN patients'… read more here.
Keywords: time interval; months median; months months; treatment ... See more keywords
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14071751
Abstract: Simple Summary This analysis assesses the efficacy of brigatinib, a next-generation ALK inhibitor in ALK+ advanced non-small cell lung cancer (aNSCLC) included in the brigatinib French Early-Access Program (1 August 2016–21 January 2019), with a… read more here.
Keywords: brigatinib; post brigatinib; months median; efficacy ... See more keywords